PMVP — Pmv Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: PMV Pharmaceuticals Announces First Patient Dosed In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt
PMV Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
PMV Pharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: PMV Pharmaceuticals Says Co Expects Reduction In Workforce To Be Fully Completed By End Of Q3 2024
Brief: Pmv Pharmaceuticals Announces Prioritization Of Pc14586 Clinical Development
Brief: PMV Pharmaceuticals Strengthens Leadership With Key Appointments As Company Advances Into Late-Stage Development
Brief: PMV Pharmaceuticals Q3 EPS USD -0.34
PMV Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview
RCS - All Active Asset Cap - Completion of further investment in Sentiance
Brief: PMV Pharmaceuticals Updates PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With TP53 Y220C Mutation
Brief: Pmv Pharmaceuticals To Present Updated Phase 1 Data On Pc14586 At The 2023 Aacr-Nci-Eortc International Conference On Molecular Targets And Cancer Therapeutics
PMV Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: PMV Pharmaceuticals Q2 EPS USD -0.38
PMV Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview
Premier Investments earnings to face pressure from soft demand - Morningstar
PMV Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: PMV Pharmaceuticals Reports First Quarter 2023 Financial Results
Brief: PMV Pharmaceuticals Reports Q1 EPS USD -0.42.
PMV Pharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview